# A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old

> **NCT03257241** · PHASE3 · UNKNOWN · sponsor: **Polish Adult Leukemia Group** · enrollment: 582 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** A arm (DA-90)
- **DRUG:** B arm (DAC)
- **DRUG:** A arm (CLAG-M)
- **DRUG:** B arm (FLAG-IDA)

## Key facts

- **NCT ID:** NCT03257241
- **Lead sponsor:** Polish Adult Leukemia Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-03
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 582 (ESTIMATED)
- **Last updated:** 2021-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03257241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03257241, "A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03257241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*